Aprea Therapeutics to Participate in the 2021 RBC Capital Markets Global Healthcare Conference
18 mai 2021 06h00 HE
|
Aprea Therapeutics
BOSTON, May 18, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
Aprea Therapeutics Reports First Quarter 2021 Financial Results and Provides Update on Business Operations
06 mai 2021 16h15 HE
|
Aprea Therapeutics
BOSTON, May 06, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the...
Aprea Therapeutics to Host Virtual R&D Day on April 22, 2021
16 avr. 2021 09h15 HE
|
Aprea Therapeutics
BOSTON, April 16, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
Aprea Therapeutics Receives FDA Orphan Drug Designation for Eprenetapopt for the Treatment of Acute Myeloid Leukemia (AML)
08 avr. 2021 11h15 HE
|
Aprea Therapeutics
BOSTON, April 08, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
Aprea Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Update on Business Operations
16 mars 2021 16h15 HE
|
Aprea Therapeutics
BOSTON, March 16, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
Aprea Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021
08 janv. 2021 08h00 HE
|
Aprea Therapeutics
BOSTON, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the...
Aprea Therapeutics Announces Results of Primary Endpoint from Phase 3 Trial of Eprenetapopt in TP53 Mutant Myelodysplastic Syndromes (MDS)
28 déc. 2020 08h00 HE
|
Aprea Therapeutics
The trial failed to meet its primary endpoint of complete remission (CR) rateCR rate was 53% higher in eprenetapopt with AZA arm compared to AZA alone, but did not reach statistical significance ...
Aprea Therapeutics Receives FDA Fast Track Designation for Eprenetapopt in the Treatment of TP53 Mutant Acute Myeloid Leukemia (AML)
30 nov. 2020 08h00 HE
|
Aprea Therapeutics
BOSTON, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the...
Aprea Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference
19 nov. 2020 08h00 HE
|
Aprea Therapeutics
BOSTON, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the...
Aprea Therapeutics Reports Third Quarter 2020 Financial Results and Provides Update on Business Operations
05 nov. 2020 16h15 HE
|
Aprea Therapeutics
BOSTON, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the...